Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment, announced its participation in two major investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10th. The company is developing novel medicines targeting the CFTR protein, with a pipeline of small molecules designed to correct defects caused by the F508del genetic mutation.

05/27/2026, 8:00 AM • GlobeNewswire

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment, announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 20th, 2026. The company is developing novel medicines targeting the CFTR protein, with a focus on NBD1 stabilizers to address the F508del genetic mutation.

05/13/2026, 8:00 AM • GlobeNewswire

Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch

A director of Sionna Therapeutics sold $2.5 million in shares (55,345 shares at $44.67 each) through OrbiMed Private Investments VIII, LP on April 17-18, 2026. Despite the 215% one-year stock surge, the sale represents only 2% of the related party's indirect holdings and reflects normal portfolio trimming. The biotech company is positioned well financially with $310 million in cash and runway into 2028, with Phase 2a data for its lead cystic fibrosis candidate expected this summer.

04/27/2026, 3:29 PM • The Motley Fool

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Sionna Therapeutics' Chief Legal Officer Jennifer Fitzpatrick exercised and immediately sold 10,250 shares on March 5, 2026, generating approximately $347,000 in proceeds. The sale represented 100% of her direct common stock holdings, though she retains 50,935 options. The transaction was pre-scheduled under a 10b5-1 plan adopted in June 2025, suggesting a planned move rather than a reactive decision. Sionna has two clinical trials with topline data expected mid-2026 and maintains $310.3 million in cash runway through 2028.

03/30/2026, 9:08 PM • The Motley Fool

A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million

OrbiMed Advisors sold 33,356 shares of Sionna Therapeutics for approximately $1.5 million on December 24, 2025, reducing its indirect holdings to 3.56 million shares. The sale represents a routine disposition as part of structured block sales, not an indication of insider concern. Sionna, a clinical-stage biotech focused on cystic fibrosis treatments, reported positive phase 1 results in June and began phase 2 trials in October, with top-line results expected mid-2026.

01/03/2026, 2:35 PM • The Motley Fool

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics initiated a Phase 2a clinical trial evaluating SION-719, a novel NBD1 stabilizer, as an addition to standard cystic fibrosis treatment Trikafta. The trial aims to assess safety, tolerability, and potential improvement in CFTR protein function, with topline data expected in mid-2026.

10/21/2025, 7:00 AM • GlobeNewswire

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatments, will participate in two upcoming investor conferences in September 2025, presenting their research on CFTR protein function normalization.

08/27/2025, 7:00 AM • GlobeNewswire